<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The levels of IL-1 alpha, IL-2, IL-6 and TNF-alpha were measured immunoradiometrically in the sera of 82 myelodysplastic (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients at diagnosis in an attempt to identify possible relationships between serum cytokine levels and clinical and laboratory parameters of the patients </plain></SENT>
<SENT sid="1" pm="."><plain>We found that serum IL-6 and TNF-alpha concentrations were significantly higher in the group of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients than in the <z:mpath ids='MPATH_458'>normal</z:mpath> controls (p &lt; 0.03 and p &lt; 0.001, respectively), while serum IL-1 alpha and IL-2 levels did not differ statistically between patients and control subjects </plain></SENT>
<SENT sid="2" pm="."><plain>Elevated serum IL-6 and TNF-alpha concentrations were mainly seen in patients with high-risk <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), i.e. patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) (p &lt; 0.05 and p &lt; 0.001, respectively), refractor <z:hpo ids='HP_0001903'>anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) (p &lt; 0.01 and p &lt; 0.001, respectively), or refrochopy <z:hpo ids='HP_0001903'>anemia</z:hpo> with excess of blasts in transformation to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) (p &lt; 0.001 and p &lt; 0.001, respectively) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with low-risk disease, i.e. patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) or <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), had serum cytokine levels comparable to those of controls </plain></SENT>
<SENT sid="4" pm="."><plain>Patients' serum IL-6 and TNF-alpha correlated inversely with the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> concentration (p &lt; 0.01 and p &lt; 0.05, respectively) and positively with the absolute number of circulating myeloblasts (p &lt; 0.01 and p &lt; 0.001, respectively) and the proportion of bone marrow (p &lt; 0.001 and p &lt; 0.001, respectively) myeloblasts </plain></SENT>
<SENT sid="5" pm="."><plain>A negative correlation was also noted between serum TNF-alpha concentrations and patients' survival in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (p &lt; 0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>We concluded that elevated serum IL-6 and TNF-alpha values are seen mainly in patients with high-risk disease, and that high serum TNF-alpha concentrations are predictive of shortened survival in this group of patients </plain></SENT>
</text></document>